Abstract
Objective:
To report the clinical features of 20 pediatric patients with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis.
Study design:
Review of clinical data, long-term follow-up, and immunologic studies performed in a single center in Spain in the last 4 years.
Results:
The median age of the patients was 13 years (range, 8 months-18 years), 70% were female. In 12 patients (60%), the initial symptoms were neurologic, usually dyskinesias or seizures, and in the other 40% psychiatric. One month into the disease, all patients had involuntary movements and alterations of behavior and speech. All patients received steroids, intravenous immunoglobulin or plasma exchange, and 7 rituximab or cyclophosphamide. With a median follow up of 17.5 months, 85% had substantial recovery, 10% moderate or severe deficits, and 1 died. Three patients had previous episodes compatible with anti-NMDAR encephalitis, 2 of them with additional relapses after the diagnosis of the disorder. Ovarian teratoma was identified in 2 patients, 1 at onset of encephalitis and the other 1 year later. Two novel observations (1 patient each) include, the identification of an electroencephalographic pattern ("extreme delta brush") considered characteristic of this disorder, and the development of anti-NMDAR encephalitis as post herpes simplex encephalitis choreoathetosis.
Conclusions:
The initial symptoms of pediatric anti-NMDAR encephalitis vary from those of the adults (more neurologic and less psychiatric in children), the development of a mono-symptomatic illness is extremely rare (except in relapses), and most patients respond to treatment. Our study suggests a link between post herpes simplex encephalitis choreoathetosis and anti-NMDAR encephalitis.
| Original language | English |
|---|---|
| Pages (from-to) | 850-856.e2 |
| Journal | Journal of Pediatrics |
| Volume | 162 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 2013 |
| Externally published | Yes |
Bibliographical note
Funding Information:Supported by the National Institutes of Health ( RO1NS077851 and RO1MH094741 to J.D.), the National Cancer Institute ( RO1CA89054 to J.D.), Fundació la Marató de TV3 (to J.D.), Fondo de Investigaciones Sanitarias ( PI11/01780 to J.D. and PS09/0193 to F.G.), a fellowship from the Dutch Cancer Society (KWF 2009-4451), and a McKnight Neuroscience of Brain Disorders award (to J.D.). J.D. has received a research grant from Euroimmun , and receives royalties from the Editorial Board of Up-To-Date and from patents for the use of Ma2 and NMDAR as autoantibody tests. The authors declare no conflicts of interest.
Fingerprint
Dive into the research topics of 'Pediatric anti-N-methyl-D-aspartate receptor encephalitis - Clinical analysis and novel findings in a series of 20 patients'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver